123 related articles for article (PubMed ID: 19479669)
1. [Comment to P. J. Olbert et al., page 164].
Heidenreich A
Aktuelle Urol; 2009 May; 40(3):169-70. PubMed ID: 19479669
[No Abstract] [Full Text] [Related]
2. [Toxicity and efficacy of intermittent docetaxel chemotherapy for hormone refractory prostate cancer].
Olbert PJ; Weil C; Hegele A; Hofmann R; Schrader AJ
Aktuelle Urol; 2009 May; 40(3):164-8. PubMed ID: 19370533
[TBL] [Abstract][Full Text] [Related]
3. [Significance of docetaxel in the chemotherapy of hormone-refractory prostate cancer].
Wolff JM
Onkologie; 2003 Dec; 26 Suppl 7():37-40. PubMed ID: 14716141
[TBL] [Abstract][Full Text] [Related]
4. An open-label, noncomparative phase II trial to evaluate the efficacy and safety of docetaxel in combination with gefitinib in patients with hormone-refractory metastatic prostate cancer.
Salzberg M; Rochlitz C; Morant R; Thalmann G; Pedrazzini A; Roggero E; Schönenberger A; Knuth A; Borner M
Onkologie; 2007 Jul; 30(7):355-60. PubMed ID: 17596743
[TBL] [Abstract][Full Text] [Related]
5. ECOG: CHAARTED--ChemoHormonal therapy versus androgen ablation randomized trial for extensive disease in prostate cancer.
Sweeney CJ
Clin Adv Hematol Oncol; 2006 Aug; 4(8):588-90. PubMed ID: 17111557
[No Abstract] [Full Text] [Related]
6. High dose pulse calcitriol, docetaxel and estramustine for androgen independent prostate cancer: a phase I/II study.
Tiffany NM; Ryan CW; Garzotto M; Wersinger EM; Beer TM
J Urol; 2005 Sep; 174(3):888-92. PubMed ID: 16093981
[TBL] [Abstract][Full Text] [Related]
7. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
Fizazi K; Faivre L; Lesaunier F; Delva R; Gravis G; Rolland F; Priou F; Ferrero JM; Houede N; Mourey L; Theodore C; Krakowski I; Berdah JF; Baciuchka M; Laguerre B; Fléchon A; Ravaud A; Cojean-Zelek I; Oudard S; Labourey JL; Chinet-Charrot P; Legouffe E; Lagrange JL; Linassier C; Deplanque G; Beuzeboc P; Davin JL; Martin AL; Habibian M; Laplanche A; Culine S
Lancet Oncol; 2015 Jul; 16(7):787-94. PubMed ID: 26028518
[TBL] [Abstract][Full Text] [Related]
8. Cabazitaxel rechallenge at prostate-specific antigen relapse after previous cabazitaxel and docetaxel chemotherapy: case report.
Perry CJ; Sundar S
Clin Genitourin Cancer; 2012 Sep; 10(3):207-9. PubMed ID: 22445962
[No Abstract] [Full Text] [Related]
9. Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Survival Results From STAMPEDE (NCT00268476).
Clin Adv Hematol Oncol; 2016 Apr; 14(4 Suppl 5):11-3. PubMed ID: 27167844
[No Abstract] [Full Text] [Related]
10. Prostate cancer chemotherapy: emerging from the shadows.
Roth BJ
J Clin Oncol; 2005 May; 23(15):3302-3. PubMed ID: 15738529
[No Abstract] [Full Text] [Related]
11. Are prostate-specific antigen changes valid surrogates for survival in hormone-refractory prostate cancer? A meta-analysis is needed!
Collette L; Buyse M; Burzykowski T
J Clin Oncol; 2007 Dec; 25(35):5673-4; author reply 5674. PubMed ID: 18065747
[No Abstract] [Full Text] [Related]
12. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators.
Beer TM; Ryan CW; Venner PM; Petrylak DP; Chatta GS; Ruether JD; Redfern CH; Fehrenbacher L; Saleh MN; Waterhouse DM; Carducci MA; Vicario D; Dreicer R; Higano CS; Ahmann FR; Chi KN; Henner WD; Arroyo A; Clow FW;
J Clin Oncol; 2007 Feb; 25(6):669-74. PubMed ID: 17308271
[TBL] [Abstract][Full Text] [Related]
13. Docetaxel plus prednisone versus mitoxantrone plus prednisone for metastatic hormone-refractory prostate cancer in Chinese patients: experience of a single center.
Zhang HL; Ye DW; Yao XD; Dai B; Zhang SL; Shen YJ; Zhu Y; Zhang W
Urol Int; 2007; 79(4):307-11. PubMed ID: 18025847
[TBL] [Abstract][Full Text] [Related]
14. Cabazitaxel for castration-resistant prostate cancer.
Froehner M; Wirth MP
Lancet; 2011 Jan; 377(9760):121-2; author reply 122-3. PubMed ID: 21215875
[No Abstract] [Full Text] [Related]
15. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
de Bono JS; Oudard S; Ozguroglu M; Hansen S; Machiels JP; Kocak I; Gravis G; Bodrogi I; Mackenzie MJ; Shen L; Roessner M; Gupta S; Sartor AO;
Lancet; 2010 Oct; 376(9747):1147-54. PubMed ID: 20888992
[TBL] [Abstract][Full Text] [Related]
16. [AUO study AP 59/10: first-line therapy of castration-resistant prostate cancer].
Rexer H
Urologe A; 2011 Jun; 50(6):722-4. PubMed ID: 21584827
[No Abstract] [Full Text] [Related]
17. [Docetaxel--standard therapy further optimized].
Krankenpfl J; 2005; 43(4-6):141. PubMed ID: 16171083
[No Abstract] [Full Text] [Related]
18. [Low-dose docetaxel, estramustine and dexamethasone combination chemotherapy for hormone-refractory prostate cancer].
Kobayashi K; Yokonishi T; Ito Y; Matsumoto T; Umemoto S; Osaka K; Nakamura M; Onuki T; Komiya A; Ohgo Y; Sakai N; Noguchi S; Kishi H; Yokomizo Y; Kawai M; Okajima K; Tajiri T; Fujikawa A; Ohta J; Yumura Y; Moriyama M
Hinyokika Kiyo; 2010 Apr; 56(4):203-7. PubMed ID: 20448443
[TBL] [Abstract][Full Text] [Related]
19. Do we really need new trials on fulvestrant in prostate cancer?
Féchon A; Droz JP
Onkologie; 2010; 33(1-2):12-3. PubMed ID: 20164656
[No Abstract] [Full Text] [Related]
20. Carboplatin plus weekly docetaxel as salvage chemotherapy in docetaxel-resistant and castration-resistant prostate cancer.
Reuter CW; Morgan MA; Ivanyi P; Fenner M; Ganser A; Grünwald V
World J Urol; 2010 Jun; 28(3):391-8. PubMed ID: 20229232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]